NRBO - NeuroBo stock rises ~10% on FDA nod to start trial of liver drug

2023-05-02 08:26:46 ET

• The U.S. Food and Drug Administration (FDA) cleared NeuroBo Pharmaceuticals' ( NASDAQ: NRBO ) investigational new drug (IND) application seeking to start a trial of liver disease drug DA-1241.
• The company plans to begin a two-part, phase 2a trial of DA-1241 to treat nonalcoholic steatohepatitis (NASH) in Q3 2023.
• The study will include people with presumed NASH and confirmed pre-diabetes or type 2 diabetes mellitus (T2DM).
• "In Phase 1a/1b clinical studies, DA-1241 was well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM)," said Joe Hooker, interim president and CEO, NeuroBo.
• NRBO +12.41% to $0.77 premarket May 2

For further details see: